June 2018, Series B
Attune is a clinical-stage biotechnology company focused on novel small-molecule therapeutics for rare diseases. Attune's lead drug is in clinical trials for the treatment of HAE and a second program is focused on complement-mediated diseases. Investors include Venrock, RTW Investments, RA Capital, Tavistock and Tang Capital.
Mentions in press and media 3